PureTech Health snags $11.4M from DOD to test hor­mone drug in rare brain dis­ease

The De­part­ment of De­fense has award­ed PureTech Health up to $11.4 mil­lion to test an ex­per­i­men­tal ther­a­py for a rare neu­rode­gen­er­a­tive dis­ease called frag­ile X-as­so­ci­at­ed tremor atax­ia syn­drome (FX­TAS), the Boston biotech told End­points News.

The dis­ease, which PureTech ex­ec­u­tives say is un­der­diag­nosed, pre­dom­i­nant­ly af­fects men in their 60s and is char­ac­ter­ized by cog­ni­tive and mo­tor dys­func­tion, in­clud­ing tremors that re­sem­ble Parkin­son’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER